Advertisement

 

 

RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.

RGS9-2 Modulates Responses to Oxycodone in Pain-Free and Chronic Pain States.
Author Information (click to view)

Gaspari S, Cogliani V, Manouras L, Anderson EM, Mitsi V, Avrampou K, Carr FB, Zachariou V,


Gaspari S, Cogliani V, Manouras L, Anderson EM, Mitsi V, Avrampou K, Carr FB, Zachariou V, (click to view)

Gaspari S, Cogliani V, Manouras L, Anderson EM, Mitsi V, Avrampou K, Carr FB, Zachariou V,

Advertisement
Share on FacebookTweet about this on TwitterShare on LinkedIn

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2017 02 08() doi 10.1038/npp.2017.4
Abstract

Regulator of G-protein signaling 9-2 (RGS9-2) is a striatal-enriched signal-transduction modulator known to have a critical role in the development of addiction-related behaviors following exposure to psychostimulants or opioids. RGS9-2 controls the function of several G-protein-coupled receptors, including dopamine receptor and mu opioid receptor (MOR). We previously showed that RGS9-2 complexes negatively control morphine analgesia, and promote the development of morphine tolerance. In contrast, RGS9-2 positively modulates the actions of other opioid analgesics, such as fentanyl and methadone. Here we investigate the role of RGS9-2 in regulating responses to oxycodone, an MOR agonist prescribed for the treatment of severe pain conditions that has addictive properties. Using mice lacking the Rgs9 gene (RGS9KO), we demonstrate that RGS9-2 positively regulates the rewarding effects of oxycodone in pain-free states, and in a model of neuropathic pain. Furthermore, although RGS9-2 does not affect the analgesic efficacy of oxycodone or the expression of physical withdrawal, it opposes the development of oxycodone tolerance, in both acute pain and chronic neuropathic pain models. Taken together, these data provide new information on the signal-transduction mechanisms that modulate the rewarding and analgesic actions of oxycodone.Neuropsychopharmacology advance online publication, 8 February 2017; doi:10.1038/npp.2017.4.

Submit a Comment

Your email address will not be published. Required fields are marked *

14 − 4 =

[ HIDE/SHOW ]